EBI-005: an Interleukin-1 Receptor Inhibitor Designed for the Treatment of Dry Eye Syndrome

Dry eye syndrome (DES) is an ocular surface inflammatory condition induced by desiccating stress and mediated by IL-1 stimulation of the Th17 pathway.1,2,3 DES affects approximately 10% of individuals between 30 to 60 years of age, and up to 15% of those over 65. Despite its prevalence and impact on quality of life, DES is under-diagnosed, under-treated and has few safe and effective treatment options.